CellCarta Acquires Reveal Biosciences to Enhance AI-Powered Pathology and Multi-Omics Biomarker Services

MONTREAL, May 11, 2021 /PRNewswire/ -- CellCarta, a global provider of precision medicine services, today announced the acquisition of Reveal Biosciences (“Reveal”), a computational pathology company headquartered in San Diego, California, that provides AI-driven quantitative pathology and immunohistochemistry services to the biopharmaceutical industry. This acquisition further solidifies CellCarta’s position as a leading provider of histopathology biomarker services and will enable the company to expand its artificial intelligence-powered multi-omics data analysis services and applications.

Reveal Biosciences has created a new generation of Pathology Intelligence™ to enhance global research, clinical trials, and improve patient outcomes. Reveal’s imageDx™ pathology platform combines cutting-edge machine learning (ML)-AI with traditional histopathology, transforming tissue biology into actionable data. Reveal’s unique proprietary pipeline architecture and biomarker-based training approach also support the development of scalable, customized AI models for specific pathological endpoints, companion diagnostics, and predictive models integrating multi-omics data.

Martin LeBlanc, CEO of CellCarta, stated, “Reveal’s superior AI and machine learning capabilities will support more objective quantification of tissue biomarkers and enable broader and faster deployment of histopathology services.” He added, “The acquisition of this leading company is part of our game-changing strategy to expand our services and better support our global customers, who are actively seeking more objective, reproducible, and scalable approaches to tissue biomarker assessment deployed within a robust quality and regulatory platform.”

“We are delighted to partner with CellCarta,” said Dr. Claire Weston, CEO and Co-Founder of Reveal Biosciences. “Reveal’s extensive portfolio of automated digital analytics serves oncology, NASH, neuroscience, fibrosis, inflammation, and other therapeutic areas. We see significant opportunity in combining these AI capabilities with CellCarta to enable better diagnostics and more meaningful clinical trials globally.”

AboutCellCarta
CellCarta is a leading provider of specialized precision medicine laboratory services for the biopharmaceutical industry. Leveraging its integrated analytical platforms in immunology, histopathology, proteomics, and genomics, along with associated specimen collection and logistics services, CellCarta supports the entire drug development lifecycle from discovery through late-stage clinical trials. The company operates globally, with 10 facilities located in Canada, the United States, Belgium, Australia, and China.

For more information, please visit:cellcarta.com

AboutReveal Biosciences 
Reveal Sciences has created a new generation of Pathology Intelligence™ to enhance global research and improve patient outcomes. Reveal’s imageDx™ pathology platform provides AI-driven data analytics and cloud-based whole-slide image management for the life sciences and healthcare sectors. With a team of data and research scientists dedicated to addressing critical challenges in healthcare, Reveal has developed a suite of AI-powered digital analytics for preclinical research, clinical trials, and diagnostics.

For more information, please visit:revealbio.com